Craig-Hallum raised the firm’s price target on Xeris Biopharma to $5 from $4.50 and keeps a Buy rating on the shares. The company reported a “nice” Q2 report, with revenue slightly above the pre-released results, the analyst tells investors. Additionally, the firm is now “confident” the appointment of John Shannon to CEO was made from a position of strength as the business is performing nicely across its portfolio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Biopharma reports Q2 EPS (10c), consensus (11c)
- Xeris Pharmaceuticals Appoints Kevin McCulloch as President and COO
- Xeris Pharmaceuticals Undergoes Executive Leadership Transition
- Xeris Biopharma reports preliminary Q2 revenue $47M, consensus $44.89M
- Xeris Biopharma CEO Paul Edick to retire, John Shannon to succeed
Questions or Comments about the article? Write to editor@tipranks.com